Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

How to access Pharma in Focus articles
  • If you're a current subscriber, See below

  • If you're new to Pharma in Focus, Click here

  • If you haven't SUBSCRIBED yet, Click here

Current Subscribers

If you are are current Full Text Subscriber or have taken out a Free Trial, please type your email address into the form below.

This will restore your access and return you to the Home Page.

Email Address
Pipeline Monitor
Regulators in a generous mood
The FDA and the EMA have been busy approving and recommending new cancer, HIV and heart failure drugs.
Working Life
Staff rate managers in industry survey
Managers in Australian pharma companies have been given a positive report card from staff in the latest industry survey, although there are significant differences between branded only, generic only and combination companies.
Approvals Action
First competitor for narcolepsy drug
The first generic competitor for Teva'smulti-million dollar narcolepsy drug Modavigil has arrived on the PBS along with a raft of additions to already listed generics.
Special Report
Aussie pharma: flat-footed in the face of change?
A heavy compliance burden, regular downsizing and senior management churn are conspiring to leave Aussie pharma flat-footed when confronted by the challenges that a year such as 2016 is expected to bring, industry insiders fear.
Company Snapshot
BMS: quality pipeline feeds growth
In our latest company snapshot, we look at the local operations of Bristol-Myers Squibb, which has a strong pipeline and some fast-growing drugs in the market.